Companies › Genprex
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| quaratusugene ozeplasmid TUSC2 gene therapy - interrupts cell signaling pathways, reestablishes cancer cell death p | TUSC2 | Phase 1 | Small Cell Lung Cancer Extensive Stage; Carcinoma, Non-Small Cell Lung | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05703971 | quaratusugene ozeplasmid | Phase 1 | Small Cell Lung Cancer Extensive Stage | Oncology | Dec 2027 |
| NCT04486833 | quaratusugene ozeplasmid | Phase 1 | Carcinoma, Non-Small Cell Lung | Oncology | Mar 2028 |
Cash of $15m on 2026-06-30; operating cash outflow about $17m a year; runway about 11 months at that burn, to May 2027
Press releases filed as 8-K in the last year:
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.